Apr4609
Bullish
now
$LPTX Because it is well known that dkn-01 doesn’t have significant adverse effects from multiple monotherapy trials and that chemo has consistent adverse effects in this trial, the trial ran as expected. The adverse effects were easily attributed to the chemo. by the experts who ran the trial and beigene (leaps partner) and therefore there were no halts by the administrators or fda. Clearly the company expected smart people would realize this simple point. If you are in doubt, simply look at dkn-01 monotherapy trials. However, the shorts and bears are trying to create something that is false by saying dkn-01 has dangerous adverse effects. Smart money always finds a way to invest in winners like leap. Lptx Strong Buy
1
11
11 Likes